Ignite Creation Date:
2025-12-24 @ 10:55 PM
Ignite Modification Date:
2026-02-02 @ 3:55 AM
Study NCT ID:
NCT04795869
Status:
WITHDRAWN
Last Update Posted:
2023-10-10
First Post:
2021-03-10
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Sponsor:
Northwestern University
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Recurrent Angioimmunoblastic T-Cell Lymphoma | View |
| None | Recurrent Enteropathy-Associated T-Cell Lymphoma | View |
| None | Recurrent Follicular T-Cell Lymphoma | View |
| None | Recurrent Hepatosplenic T-Cell Lymphoma | View |
| None | Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | View |
| None | Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified | View |
| None | Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma | View |
| None | Refractory Angioimmunoblastic T-Cell Lymphoma | View |
| None | Refractory Enteropathy-Associated T-Cell Lymphoma | View |
| None | Refractory Follicular T-Cell Lymphoma | View |
| None | Refractory Hepatosplenic T-Cell Lymphoma | View |
| None | Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | View |
| None | Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified | View |
| None | Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma | View |
Keywords: